Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has received clinical trial approval from the National Medical Products Administration (NMPA) for its oral probiotic preparation, WST04, aimed at treating advanced malignant solid tumors.
Preclinical studies indicate that WST04 significantly enhances the anti-tumor efficacy of immune checkpoint inhibitors, positioning it as a potential adjunct therapy in oncology. Shanghai Pharmaceuticals has invested approximately RMB 6.43 million in the development of this promising drug.- Flcube.com
